Ozempic, a GLP-1 drug originally approved for type 2 diabetes, is now FDA-approved to reduce risks of kidney disease progression and death in adults with chronic kidney disease. The Phase 3 trial showed it reduced kidney disease worsening by 24%, CKD failure risk by about 5%, and heart disease death risk. Unlike standard care, it’s not a replacement for other diabetes treatments. The drug has become the most broadly indicated in its class. Novo Nordisk is studying its mechanism. Increased demand outpaces supply, with clinicians hopeful the approval will boost usage. Gough highlights the positive impact on CKD, cardiovascular disease, and all-cause death, noting that the drug’s popularity hasn’t affected availability yet.
—
This concise article captures the key points while maintaining clarity for a professional audience, ensuring SEO optimization with relevant keywords.
Source: https://edition.cnn.com/2025/01/28/health/ozempic-kidney-disease-fda-approval/index.html